Search Results - subject:"Citalopram"

Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed P...

Shih, Ya-Chen Tina; Bekele, Nebiyou B.; Xu, Ying - In: PharmacoEconomics 25 (2007) 10, pp. 843-862

compared the cost effectiveness of sertraline, citalopram, escitalopram and fluoxetine with paroxetine in elderly depressed … of generic paroxetine, and that, after the entry of generic paroxetine, citalopram and escitalopram were dominated by … sertraline, citalopram, escitalopram or fluoxetine was more cost effective than paroxetine was 96.7%, 77.6%, 96.3% and 97 …

Persistent link: https://www.econbiz.de/10005449194

The Importance of Achieving Additional Drug Benefits at a Reasonable Cost: A Review of the Fluoxetine Years

Freemantle, Nick; Mason, James - In: PharmacoEconomics 17 (2000) 4, pp. 319-324

Fluoxetine continues to be remarkably successful; greater volumes of this drug are sold than for any other antidepressant in the world. Prozac(R) has also become a household name. In this article we examine the circumstances that surround this success, and the evidence base that supports it....

Persistent link: https://www.econbiz.de/10005243117

Mirtazapine: A Pharmacoeconomic Review of its Use in Depression

Holm, Kristin J.; Jarvis, Blair; Foster, Rachel H. - In: PharmacoEconomics 17 (2000) 5, pp. 515-534

. Mirtazapine improved quality of life to a similar extent to fluoxetine, citalopram and paroxetine in unpublished studies of 6 and … and citalopram in quality of life after 2 and 4 weeks, although confirmation is required. In a decision analytical model …

Persistent link: https://www.econbiz.de/10005405002

A Critical Review of Published Economic Modelling Studies in Depression

Jones, Michael T.; Cockrum, Paul C. - In: PharmacoEconomics 17 (2000) 6, pp. 555-583

Depression is a very costly chronic disease. An important cost driver is treatment failure caused by patient noncompliance due, in part, to the adverse effects of medications. Additionally, inadequate duration of therapy and inappropriate medication switching contribute to the high cost of...

Persistent link: https://www.econbiz.de/10005590336